

Ian Reid

List of Publications by Year in Descending Order

Source: <https://exaly.com/author-pdf/488820/ian-reid-publications-by-year.pdf>

Version: 2024-04-19

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

400
papers

31,298
citations

91
h-index

168
g-index

444
ext. papers

35,187
ext. citations

7.2
avg, IF

7.36
L-index

#	Paper	IF	Citations
400	Drug therapy for osteoporosis in older adults.. <i>Lancet, The</i> , 2022 , 399, 1080-1092	4.0	11
399	Revisiting osteoporosis guidelines. <i>Lancet Diabetes and Endocrinology,the</i> , 2021 , 9, 805-806	18.1	1
398	Effect of Zoledronate on Lower Respiratory Infections in Older Women: Secondary Analysis of a Randomized Controlled Trial. <i>Calcified Tissue International</i> , 2021 , 109, 12-16	3.9	6
397	Dietary calcium intake and change in bone mineral density in older adults: a systematic review of longitudinal cohort studies. <i>European Journal of Clinical Nutrition</i> , 2021 ,	5.2	3
396	Bone-friendly lifestyle and the role of calcium or vitamin D supplementation. <i>Climacteric</i> , 2021 , 1-6	3.1	0
395	Elevated Urate Levels Do Not Alter Bone Turnover Markers: Randomized Controlled Trial of Inosine Supplementation in Postmenopausal Women. <i>Arthritis and Rheumatology</i> , 2021 , 73, 1758-1764	9.5	1
394	Consensus Statement on the Use of Bone Turnover Markers for Short-Term Monitoring of Osteoporosis Treatment in the Asia-Pacific Region. <i>Journal of Clinical Densitometry</i> , 2021 , 24, 3-13	3.5	18
393	Predictors of Fracture in Older Women With Osteopenic Hip Bone Mineral Density Treated With Zoledronate. <i>Journal of Bone and Mineral Research</i> , 2021 , 36, 61-66	6.3	5
392	Development of the Asia Pacific Consortium on Osteoporosis (APCO) Framework: clinical standards of care for the screening, diagnosis, and management of osteoporosis in the Asia-Pacific region. <i>Osteoporosis International</i> , 2021 , 32, 1249-1275	5.3	4
391	Molecular characterisation of osteoblasts from bone obtained from people of Polynesian and European ancestry undergoing joint replacement surgery. <i>Scientific Reports</i> , 2021 , 11, 2428	4.9	0
390	Bisphosphonate holidays. <i>Drug and Therapeutics Bulletin</i> , 2021 , 59, 35-36	0.9	1
389	The Interaction of Acute-Phase Reaction and Efficacy for Osteoporosis After Zoledronic Acid: HORIZON Pivotal Fracture Trial. <i>Journal of Bone and Mineral Research</i> , 2021 ,	6.3	1
388	Bone Mineral Density and Bone Turnover 10 Years After a Single 5 mg Dose or Two 5-Yearly Lower Doses of Zoledronate in Osteopenic Older Women: An Open-Label Extension of a Randomized Controlled Trial. <i>Journal of Bone and Mineral Research</i> , 2021 ,	6.3	1
387	Nitrates Do Not Affect Bone Density or Bone Turnover in Postmenopausal Women: A Randomized Controlled Trial. <i>Journal of Bone and Mineral Research</i> , 2020 , 35, 1040-1047	6.3	3
386	The effect of age on the microarchitecture and profile of gene expression in femoral head and neck bone from patients with osteoarthritis. <i>Bone Reports</i> , 2020 , 13, 100287	2.6	0
385	A broader strategy for osteoporosis interventions. <i>Nature Reviews Endocrinology</i> , 2020 , 16, 333-339	15.2	43
384	Osteoporosis: evidence for vitamin D and calcium in older people. <i>Drug and Therapeutics Bulletin</i> , 2020 , 58, 122-125	0.9	7

383	Ten Years of Very Infrequent Zoledronate Therapy in Older Women: An Open-Label Extension of a Randomized Trial. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2020 , 105,	5.6	18
382	Zoledronate. <i>Bone</i> , 2020 , 137, 115390	4.7	12
381	What factors modify the effect of monthly bolus dose vitamin D supplementation on 25-hydroxyvitamin D concentrations?. <i>Journal of Steroid Biochemistry and Molecular Biology</i> , 2020 , 201, 105687	5.1	7
380	Effects of Zoledronate on Cancer, Cardiac Events, and Mortality in Osteopenic Older Women. <i>Journal of Bone and Mineral Research</i> , 2020 , 35, 20-27	6.3	34
379	Zoledronate Slows Weight Loss and Maintains Fat Mass in Osteopenic Older Women: Secondary Analysis of a Randomized Controlled Trial. <i>Calcified Tissue International</i> , 2020 , 106, 386-391	3.9	2
378	Management of Paget's disease of bone. <i>Osteoporosis International</i> , 2020 , 31, 827-837	5.3	7
377	No more fracture trials in osteoporosis?. <i>Lancet Diabetes and Endocrinology</i> , 2020 , 8, 650-651	18.1	3
376	Benefits of Bisphosphonate Therapy: Beyond the Skeleton. <i>Current Osteoporosis Reports</i> , 2020 , 18, 587-596	5.4	9
375	A prediction tool for vitamin D deficiency in New Zealand adults. <i>Archives of Osteoporosis</i> , 2020 , 15, 172	2.9	2
374	Calcium and Bone. <i>Handbook of Experimental Pharmacology</i> , 2020 , 262, 259-280	3.2	1
373	Reply to Serious Adverse Events With Romosozumab Use in Japanese Patients: Need for Clear Formulation of Contraindications Worldwide. <i>Journal of Bone and Mineral Research</i> , 2020 , 35, 996-997	6.3	2
372	Calcium and/or Vitamin D Supplementation for the Prevention of Fragility Fractures: Who Needs It?. <i>Nutrients</i> , 2020 , 12,	6.7	19
371	Effect of Zoledronate on Bone Loss After Romosozumab/Denosumab: 2-Year Follow-up. <i>Calcified Tissue International</i> , 2019 , 105, 107-108	3.9	14
370	Anti-fracture efficacy of zoledronate in subgroups of osteopenic postmenopausal women: secondary analysis of a randomized controlled trial. <i>Journal of Internal Medicine</i> , 2019 , 286, 221-229	10.8	11
369	Dietary Calcium Intake and Bone Loss Over 6 Years in Osteopenic Postmenopausal Women. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2019 , 104, 3576-3584	5.6	19
368	Fibroblast growth factor 23 levels decline following sleeve gastrectomy. <i>Clinical Endocrinology</i> , 2019 , 91, 87-93	3.4	2
367	Pathogenesis of Osteoporosis 2019 , 222-232		1
366	Bisphosphonates for Prevention of Bone Loss in Glucocorticoid-Treated Young People. <i>EClinicalMedicine</i> , 2019 , 12, 8-9	11.3	1

365	Bone-Bound Bisphosphonates Inhibit Proliferation of Breast Cancer Cells. <i>Calcified Tissue International</i> , 2019 , 105, 497-505	3.9	6
364	Long-Term Stable Bone Mineral Density in HIV-Infected Men Without Risk Factors for Osteoporosis Treated with Antiretroviral Therapy. <i>Calcified Tissue International</i> , 2019 , 105, 423-429	3.9	2
363	Controversies in medicine: the role of calcium and vitamin D supplements in adults. <i>Medical Journal of Australia</i> , 2019 , 211, 468-473	4	17
362	Odanacatib for the treatment of postmenopausal osteoporosis: results of the LOFT multicentre, randomised, double-blind, placebo-controlled trial and LOFT Extension study. <i>Lancet Diabetes and Endocrinology</i> , 2019 , 7, 899-911	18.1	61
361	Recent advances in understanding and managing Paget's disease. <i>F1000Research</i> , 2019 , 8,	3.6	2
360	Osteomalacia in subtropical Auckland. <i>BMJ Case Reports</i> , 2019 , 12,	0.9	1
359	Longitudinal changes in bone mineral density, bone mineral content and bone area at the lumbar spine and hip in postmenopausal women, and the influence of abdominal aortic calcification. <i>Bone Reports</i> , 2019 , 10, 100190	2.6	3
358	25-Hydroxyvitamin D Threshold for the Effects of Vitamin D Supplements on Bone Density: Secondary Analysis of a Randomized Controlled Trial. <i>Journal of Bone and Mineral Research</i> , 2018 , 33, 1464-1469	6.3	63
357	Bone Loss After Romosozumab/Denosumab: Effects of Bisphosphonates. <i>Calcified Tissue International</i> , 2018 , 103, 55-61	3.9	58
356	Lack of Evidence that Soluble Urate Directly Influences Bone Remodelling: A Laboratory and Clinical Study. <i>Calcified Tissue International</i> , 2018 , 102, 73-84	3.9	4
355	Calcium and vitamin D do not prevent fractures in community-dwelling adults. <i>BMJ Evidence-Based Medicine</i> , 2018 , 23, 185-186	2.7	
354	Effects of Leptin on the Skeleton. <i>Endocrine Reviews</i> , 2018 , 39, 938-959	27.2	56
353	Fracture Prevention with Zoledronate in Older Women with Osteopenia. <i>New England Journal of Medicine</i> , 2018 , 379, 2407-2416	59.2	174
352	Long-Term Effects of Intravenous Ibandronate in Paget's Disease of Bone. <i>Calcified Tissue International</i> , 2017 , 100, 250-254	3.9	8
351	Effect of single-dose dexamethasone on acute phase response following zoledronic acid: a randomized controlled trial. <i>Osteoporosis International</i> , 2017 , 28, 1867-1874	5.3	7
350	Long-Term Bone Scintigraphy Results After Intravenous Zoledronate in Paget's Disease of Bone. <i>Calcified Tissue International</i> , 2017 , 101, 43-49	3.9	7
349	Bone Loss After Denosumab: Only Partial Protection with Zoledronate. <i>Calcified Tissue International</i> , 2017 , 101, 371-374	3.9	74
348	Dietary calcium intake and rate of bone loss in men. <i>British Journal of Nutrition</i> , 2017 , 117, 1432-1438	3.6	12

347	Serum phosphate is related to adiposity in healthy adults. <i>European Journal of Clinical Investigation</i> , 2017 , 47, 486-493	4.6	10
346	Targeting Sclerostin in Postmenopausal Osteoporosis: Focus on Romosozumab and Blosozumab. <i>BioDrugs</i> , 2017 , 31, 289-297	7.9	10
345	Case-Based Review of Osteonecrosis of the Jaw (ONJ) and Application of the International Recommendations for Management From the International Task Force on ONJ. <i>Journal of Clinical Densitometry</i> , 2017 , 20, 8-24	3.5	125
344	Vitamin D Effect on Bone Mineral Density and Fractures. <i>Endocrinology and Metabolism Clinics of North America</i> , 2017 , 46, 935-945	5.5	34
343	Calcium and Cardiovascular Disease. <i>Endocrinology and Metabolism</i> , 2017 , 32, 339-349	3.5	46
342	Duration of antiresorptive activity of zoledronate in postmenopausal women with osteopenia: a randomized, controlled multidose trial. <i>Cmaj</i> , 2017 , 189, E1130-E1136	3.5	26
341	Effect of monthly high-dose vitamin D on bone density in community-dwelling older adults substudy of a randomized controlled trial. <i>Journal of Internal Medicine</i> , 2017 , 282, 452-460	10.8	66
340	Are more trials of calcium supplements really needed?. <i>Osteoporosis International</i> , 2017 , 28, 2729-2730	5.3	1
339	Calcium Intake and Cardiovascular Disease Risk. <i>Annals of Internal Medicine</i> , 2017 , 166, 684-685	8	7
338	Durability of Response to Zoledronate Treatment and Competing Mortality in Paget's Disease of Bone. <i>Journal of Bone and Mineral Research</i> , 2017 , 32, 753-756	6.3	25
337	Goal-Directed Treatment for Osteoporosis: A Progress Report From the ASBMR-NOF Working Group on Goal-Directed Treatment for Osteoporosis. <i>Journal of Bone and Mineral Research</i> , 2017 , 32, 3-10	6.3	94
336	Acute effects of calcium supplements on blood pressure: randomised, crossover trial in postmenopausal women. <i>Osteoporosis International</i> , 2017 , 28, 119-125	5.3	4
335	Further major uncorrected errors in National Osteoporosis Foundation meta-analyses of calcium and vitamin D supplementation in fracture prevention. <i>Osteoporosis International</i> , 2017 , 28, 733-734	5.3	7
334	What diseases are causally linked to vitamin D deficiency?. <i>Archives of Disease in Childhood</i> , 2016 , 101, 185-9	2.2	28
333	Postmenopausal osteoporosis. <i>Nature Reviews Disease Primers</i> , 2016 , 2, 16069	51.1	263
332	Errors in NOF meta-analyses of calcium and vitamin D supplements. <i>Osteoporosis International</i> , 2016 , 27, 2637-9	5.3	4
331	Vitamin D supplements do not prevent falls. <i>BMJ, The</i> , 2016 , 353, i3005	5.9	1
330	Treatment of Paget's Disease of Bone with Denosumab: Case Report and Literature Review. <i>Calcified Tissue International</i> , 2016 , 99, 322-5	3.9	36

329	Circulating calcium concentrations, vascular disease and mortality: a systematic review. <i>Journal of Internal Medicine</i> , 2016 , 279, 524-40	10.8	61
328	Reasons for discrepancies in hip fracture risk estimates using FRAX and Garvan calculators. <i>Maturitas</i> , 2016 , 85, 11-8	5	4
327	Continuous treatment with odanacatib for up to 8 years in postmenopausal women with low bone mineral density: a phase 2 study. <i>Osteoporosis International</i> , 2016 , 27, 2099-107	5.3	24
326	Path Analysis Identifies Receptor Activator of Nuclear Factor- κ B Ligand, Osteoprotegerin, and Sclerostin as Potential Mediators of the Tophus-bone Erosion Relationship in Gout. <i>Journal of Rheumatology</i> , 2016 , 43, 445-9	4.1	5
325	Relationship Between Changes in Serum Urate and Bone Mineral Density During Treatment with Thiazide Diuretics: Secondary Analysis from a Randomized Controlled Trial. <i>Calcified Tissue International</i> , 2016 , 98, 474-8	3.9	5
324	Parathyroid hormone reflects adiposity and cardiometabolic indices but not bone density in normal men. <i>BoneKEy Reports</i> , 2016 , 5, 852		4
323	Treatment of Paget's Disease of Bone 2016 , 119-136		1
322	Towards a trial-based definition of vitamin D deficiency. <i>Lancet Diabetes and Endocrinology</i> , 2016 , 4, 376-7	18.1	10
321	Acute and 3-month effects of calcium carbonate on the calcification propensity of serum and regulators of vascular calcification: secondary analysis of a randomized controlled trial. <i>Osteoporosis International</i> , 2016 , 27, 1209-1216	5.3	8
320	Effects of vitamin D supplements on bone density. <i>Journal of Endocrinological Investigation</i> , 2015 , 38, 91-4	5.2	16
319	The Effects of Re-challenge in Patients with a History of Acute Anterior Uveitis Following Intravenous Zoledronate. <i>Calcified Tissue International</i> , 2015 , 97, 58-61	3.9	8
318	Bone density is normal and does not change over 2 years in sarcoidosis. <i>Osteoporosis International</i> , 2015 , 26, 611-6	5.3	8
317	Short-term and long-term effects of osteoporosis therapies. <i>Nature Reviews Endocrinology</i> , 2015 , 11, 418-28	15.2	117
316	Calcium intake and bone mineral density: systematic review and meta-analysis. <i>BMJ, The</i> , 2015 , 351, h4183	9.3	196
315	Calcium intake and risk of fracture: systematic review. <i>BMJ, The</i> , 2015 , 351, h4580	5.9	169
314	Should we prescribe calcium or vitamin D supplements to treat or prevent osteoporosis?. <i>Climacteric</i> , 2015 , 18 Suppl 2, 22-31	3.1	32
313	Vitamin D Supplements and the Risk of Falls. <i>JAMA Internal Medicine</i> , 2015 , 175, 1723-4	11.5	4
312	Decade in review-bone: Great strides made but still further to go. <i>Nature Reviews Endocrinology</i> , 2015 , 11, 633-4	15.2	2

311	Efficacy, effectiveness and side effects of medications used to prevent fractures. <i>Journal of Internal Medicine</i> , 2015 , 277, 690-706	10.8	58
310	Cardiovascular complications of calcium supplements. <i>Journal of Cellular Biochemistry</i> , 2015 , 116, 494-504	17	22
309	Diagnosis and management of osteonecrosis of the jaw: a systematic review and international consensus. <i>Journal of Bone and Mineral Research</i> , 2015 , 30, 3-23	6.3	680
308	Calcium supplements increase risk of myocardial infarction. <i>Journal of Bone and Mineral Research</i> , 2015 , 30, 389-90	6.3	12
307	Relationship between pretreatment rate of bone loss and bone density response to once-yearly ZOL: HORIZON-PFT extension study. <i>Journal of Bone and Mineral Research</i> , 2015 , 30, 570-4	6.3	15
306	Skeletal health in adults with HIV infection. <i>Lancet Diabetes and Endocrinology</i> , 2015 , 3, 63-74	18.1	28
305	Incidence of ocular side effects with intravenous zoledronate: secondary analysis of a randomized controlled trial. <i>Osteoporosis International</i> , 2015 , 26, 499-503	5.3	25
304	Vitamin D: the more we know, the less we know. <i>Clinical Chemistry</i> , 2015 , 61, 462-5	5.5	22
303	Bone density in healthy men after cessation of calcium supplements: 20-month follow-up of a randomized controlled trial. <i>Osteoporosis International</i> , 2015 , 26, 173-8	5.3	1
302	Acute effects of calcium citrate with or without a meal, calcium-fortified juice and a dairy product meal on serum calcium and phosphate: a randomised cross-over trial. <i>British Journal of Nutrition</i> , 2015 , 113, 1585-94	3.6	22
301	Acute effects of calcium supplements on blood pressure and blood coagulation: secondary analysis of a randomised controlled trial in post-menopausal women. <i>British Journal of Nutrition</i> , 2015 , 114, 1868-74	3.6	19
300	Calcium supplements: benefits and risks. <i>Journal of Internal Medicine</i> , 2015 , 278, 354-68	10.8	79
299	Screening for vitamin D deficiency. <i>Annals of Internal Medicine</i> , 2015 , 162, 736-7	8	
298	The effect of 6 versus 9 years of zoledronic acid treatment in osteoporosis: a randomized second extension to the HORIZON-Pivotal Fracture Trial (PFT). <i>Journal of Bone and Mineral Research</i> , 2015 , 30, 934-44	6.3	152
297	Concordance of Results from Randomized and Observational Analyses within the Same Study: A Re-Analysis of the Women's Health Initiative Limited-Access Dataset. <i>PLoS ONE</i> , 2015 , 10, e0139975	3.7	9
296	Response to the letter by Asik M., et al. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2015 , 100, L36	5.6	
295	Effects of up to 5 years of denosumab treatment on bone histology and histomorphometry: the FREEDOM study extension. <i>Journal of Bone and Mineral Research</i> , 2014 , 29, 2051-6	6.3	47
294	Vitamin D supplementation and falls: a trial sequential meta-analysis. <i>Lancet Diabetes and Endocrinology</i> , 2014 , 2, 573-80	18.1	127

293	The effect of vitamin D supplementation on skeletal, vascular, or cancer outcomes: a trial sequential meta-analysis. <i>Lancet Diabetes and Endocrinology,the</i> , 2014 , 2, 307-320	18.1	294
292	Multistage genome-wide association meta-analyses identified two new loci for bone mineral density. <i>Human Molecular Genetics</i> , 2014 , 23, 1923-33	5.6	113
291	Effects of vitamin D supplements on bone mineral density: a systematic review and meta-analysis. <i>Lancet, The</i> , 2014 , 383, 146-55	40	381
290	Cardiovascular endocrinology: controversy--cardiovascular effects of calcium supplementation. <i>Nature Reviews Endocrinology</i> , 2014 , 10, 641-2	15.2	3
289	Zoledronate for prevention of bone erosion in tophaceous gout: a randomised, double-blind, placebo-controlled trial. <i>Annals of the Rheumatic Diseases</i> , 2014 , 73, 1044-51	2.4	19
288	Authors' reply. <i>Lancet Diabetes and Endocrinology,the</i> , 2014 , 2, 541	18.1	
287	Skeletal and nonskeletal effects of vitamin D: is vitamin D a tonic for bone and other tissues?. <i>Osteoporosis International</i> , 2014 , 25, 2347-57	5.3	37
286	The skeletal effects of pioglitazone in type 2 diabetes or impaired glucose tolerance: a randomized controlled trial. <i>European Journal of Endocrinology</i> , 2014 , 170, 255-62	6.5	32
285	The effect of vitamin D supplementation on skeletal, vascular, or cancer outcomes--authors' reply. <i>Lancet Diabetes and Endocrinology,the</i> , 2014 , 2, 364-5	18.1	9
284	Vitamin D supplements do not reduce mortality risk. <i>BMJ, The</i> , 2014 , 348, g2860	5.9	2
283	Calcium, phosphate and magnesium 2014 , 93-123		1
282	Metabolic bone disease 2014 , 604-635		9
281	Vitamin and mineral supplements in the primary prevention of cardiovascular disease and cancer. <i>Annals of Internal Medicine</i> , 2014 , 160, 655-6	8	2
280	Should we prescribe calcium supplements for osteoporosis prevention?. <i>Journal of Bone Metabolism</i> , 2014 , 21, 21-8	2.7	31
279	Response to letter to editor. <i>Osteoporosis International</i> , 2014 , 25, 2501	5.3	
278	Acute and 3-month effects of microcrystalline hydroxyapatite, calcium citrate and calcium carbonate on serum calcium and markers of bone turnover: a randomised controlled trial in postmenopausal women. <i>British Journal of Nutrition</i> , 2014 , 112, 1611-20	3.6	35
277	Differences in overlapping meta-analyses of vitamin D supplements and falls. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2014 , 99, 4265-72	5.6	44
276	Reassessment of fracture risk in women after 3 years of treatment with zoledronic acid: when is it reasonable to discontinue treatment?. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2014 , 99, 4546-54 ⁶		89

275	Intervals between bone density testing. <i>Journal of Bone and Mineral Research</i> , 2014 , 29, 389-91	6.3	3
274	Paget's disease of bone: an endocrine society clinical practice guideline. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2014 , 99, 4408-22	5.6	102
273	Genetic determinants of heel bone properties: genome-wide association meta-analysis and replication in the GEFOS/GENOMOS consortium. <i>Human Molecular Genetics</i> , 2014 , 23, 3054-68	5.6	78
272	Duration of antiresorptive effects of low-dose zoledronate in osteopenic postmenopausal women: a randomized, placebo-controlled trial. <i>Journal of Bone and Mineral Research</i> , 2014 , 29, 166-72	6.3	19
271	Benefits of calcium supplements are too small for clinical equipoise to exist. <i>Journal of Bone and Mineral Research</i> , 2014 , 29, 1914-5	6.3	1
270	Vitamin D supplements and bone mineral density - Authors' reply. <i>Lancet, The</i> , 2014 , 383, 1293-1294	4.0	1
269	The Auckland calcium study: 5-year post-trial follow-up. <i>Osteoporosis International</i> , 2014 , 25, 297-304	5.3	17
268	Government funding of health research in New Zealand. <i>New Zealand Medical Journal</i> , 2014 , 127, 25-30	0.8	2
267	Translation of research into clinical practice: a case study of calcium supplement prescribing in New Zealand. <i>New Zealand Medical Journal</i> , 2014 , 127, 94-101	0.8	3
266	Calcium supplements and cardiovascular risk in the Women's Health Initiative. <i>Osteoporosis International</i> , 2013 , 24, 2371-2	5.3	4
265	Testosterone levels following decreases in serum osteocalcin. <i>Calcified Tissue International</i> , 2013 , 93, 133-6	3.9	11
264	No reduction in circulating preosteoclasts 18 months after treatment with zoledronate: analysis from a randomized placebo controlled trial. <i>Calcified Tissue International</i> , 2013 , 92, 1-5	3.9	3
263	Goal-directed treatment of osteoporosis. <i>Journal of Bone and Mineral Research</i> , 2013 , 28, 433-8	6.3	47
262	Effects of antiresorptive therapies on glucose metabolism: results from the FIT, HORIZON-PFT, and FREEDOM trials. <i>Journal of Bone and Mineral Research</i> , 2013 , 28, 1348-54	6.3	87
261	Osteoporosis treatment: focus on safety. <i>European Journal of Internal Medicine</i> , 2013 , 24, 691-7	3.9	23
260	Overview of Pathogenesis 2013 , 357-360		4
259	Skeletal actions of fasting-induced adipose factor (FIAF). <i>Endocrinology</i> , 2013 , 154, 4685-94	4.8	5
258	Comment on Kanis et al.: Pitfalls in the external validation of FRAX. <i>Osteoporosis International</i> , 2013 , 24, 389-90	5.3	7

257	The impact of dietary calcium intake and vitamin D status on the effects of zoledronate. <i>Osteoporosis International</i> , 2013 , 24, 349-54	5.3	17
256	The incidence of acute anterior uveitis after intravenous zoledronate. <i>Ophthalmology</i> , 2013 , 120, 773-6	7.3	43
255	Calcium supplements and cancer risk: a meta-analysis of randomised controlled trials. <i>British Journal of Nutrition</i> , 2013 , 110, 1384-93	3.6	67
254	Long-chain triazolyl acids as inhibitors of osteoclastogenesis. <i>Bioorganic and Medicinal Chemistry</i> , 2013 , 21, 4112-9	3.4	3
253	Reduction in the risk of clinical fractures after a single dose of zoledronic Acid 5 milligrams. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2013 , 98, 557-63	5.6	64
252	Calcium supplements and cardiovascular risk: 5 years on. <i>Therapeutic Advances in Drug Safety</i> , 2013 , 4, 199-210	3.5	51
251	Randomised controlled trial of vitamin D supplementation in sarcoidosis. <i>BMJ Open</i> , 2013 , 3, e003562	3	28
250	Subgroup analysis for the risk of cardiovascular disease with calcium supplements. <i>BoneKEy Reports</i> , 2013 , 2, 293		12
249	Re-treatment of relapsed Paget's disease of bone with zoledronic acid: results from an open-label study. <i>BoneKEy Reports</i> , 2013 , 2, 442		10
248	Low-dose fluoride in postmenopausal women: a randomized controlled trial. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2013 , 98, 2301-7	5.6	15
247	Differences between self-reported and verified adverse cardiovascular events in a randomised clinical trial. <i>BMJ Open</i> , 2013 , 3,	3	14
246	What is the appropriate MHRA regulatory response to calcium's increased cardiovascular risk?. <i>BMJ, The</i> , 2013 , 346, f3413	5.9	1
245	Vitamin D and its Metabolites and Analogs in the Management of Osteoporosis 2013 , 1701-1737		
244	Observational studies--just telling us what we want to hear or telling us where we need to look?. <i>Journal of Bone and Mineral Research</i> , 2013 , 28, 980-3	6.3	1
243	An inappropriate response?. <i>BMJ, The</i> , 2013 , 346, f942	5.9	2
242	Cardiovascular effects of calcium supplements. <i>Nutrients</i> , 2013 , 5, 2522-9	6.7	27
241	Calcium and cardiovascular risks. <i>Australian Prescriber</i> , 2013 , 36, 5-8	1.4	4
240	Cardiovascular Safety of Calcium Supplements 2013 , 365-372		1

239	Relationships Between Body Fat and Bone Mass 2013 , 83-92		1
238	All people should wear sunscreen or other protection for their skin whenever they are exposed to sunlight: no. <i>Journal of Primary Health Care</i> , 2013 , 5, 156-7	0.8	
237	Stable bone mineral density over 6 years in HIV-infected men treated with highly active antiretroviral therapy (HAART). <i>Clinical Endocrinology</i> , 2012 , 76, 643-8	3.4	22
236	Relationship between bone mineral density changes with denosumab treatment and risk reduction for vertebral and nonvertebral fractures. <i>Journal of Bone and Mineral Research</i> , 2012 , 27, 687-93	6.3	139
235	Paget's disease of bone. <i>Clinical Biochemistry</i> , 2012 , 45, 43-8	3.5	27
234	Reprint: Paget's disease of bone. <i>Clinical Biochemistry</i> , 2012 , 45, 970-5	3.5	9
233	Pharmacotherapy of Paget's disease of bone. <i>Expert Opinion on Pharmacotherapy</i> , 2012 , 13, 637-46	4	13
232	Genome-wide meta-analysis identifies 56 bone mineral density loci and reveals 14 loci associated with risk of fracture. <i>Nature Genetics</i> , 2012 , 44, 491-501	36.3	866
231	Calcium supplements and risk of myocardial infarction: an hypothesis twice tested. <i>American Journal of Medicine</i> , 2012 , 125, e15; author reply e17	2.4	7
230	Five years of anti-resorptive activity after a single dose of zoledronate--results from a randomized double-blind placebo-controlled trial. <i>Bone</i> , 2012 , 50, 1389-93	4.7	60
229	Low-dose zoledronate in osteopenic postmenopausal women: a randomized controlled trial. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2012 , 97, 286-92	5.6	34
228	Role of vitamin D deficiency in cardiovascular disease. <i>Heart</i> , 2012 , 98, 609-14	5.1	35
227	The effect of 3 versus 6 years of zoledronic acid treatment of osteoporosis: a randomized extension to the HORIZON-Pivotal Fracture Trial (PFT). <i>Journal of Bone and Mineral Research</i> , 2012 , 27, 243-54	6.3	397
226	Misclassification does not explain increased cardiovascular risks of calcium supplements. <i>Journal of Bone and Mineral Research</i> , 2012 , 27, 959; author reply 960-1	6.3	7
225	Postmenopausal osteoporosis treatment with antiresorptives: effects of discontinuation or long-term continuation on bone turnover and fracture risk--a perspective. <i>Journal of Bone and Mineral Research</i> , 2012 , 27, 963-74	6.3	75
224	Time to onset of antifracture efficacy and year-by-year persistence of effect of zoledronic acid in women with osteoporosis. <i>Journal of Bone and Mineral Research</i> , 2012 , 27, 1487-93	6.3	11
223	Relationship of changes in total hip bone mineral density to vertebral and nonvertebral fracture risk in women with postmenopausal osteoporosis treated with once-yearly zoledronic acid 5 mg: the HORIZON-Pivotal Fracture Trial (PFT). <i>Journal of Bone and Mineral Research</i> , 2012 , 27, 1627-34	6.3	92
222	WNT16 influences bone mineral density, cortical bone thickness, bone strength, and osteoporotic fracture risk. <i>PLoS Genetics</i> , 2012 , 8, e1002745	6	192

221	Reply to RT Chlebowski et al. <i>American Journal of Clinical Nutrition</i> , 2012 , 95, 259-259	7	1
220	Effects of skim milk powder enriched with glycomacropeptide and G600 milk fat extract on frequency of gout flares: a proof-of-concept randomised controlled trial. <i>Annals of the Rheumatic Diseases</i> , 2012 , 71, 929-34	2.4	66
219	Comment: Assessing the potential adverse consequences of supplemental calcium on cardiovascular outcomes: should we change our approach to bone health?. <i>Annals of Pharmacotherapy</i> , 2012 , 46, 1267-8; author reply 1268-9	2.9	
218	Effects of intravenous zoledronate on bone turnover and bone density persist for at least five years in HIV-infected men. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2012 , 97, 1922-8	5.6	46
217	Re: Severe vitamin D deficiency: a prerequisite for chronic obstructive pulmonary disease responsiveness to vitamin D supplementation?. <i>Annals of Internal Medicine</i> , 2012 , 156, 904; author reply 904-5	8	
216	Epidemiology and pathogenesis of osteonecrosis of the jaw. <i>Nature Reviews Rheumatology</i> , 2011 , 8, 90-8.1	8.1	122
215	Bisphosphonates in Paget's disease. <i>Bone</i> , 2011 , 49, 89-94	4.7	29
214	Bone-bound bisphosphonate inhibits growth of adjacent non-bone cells. <i>Bone</i> , 2011 , 49, 710-6	4.7	49
213	Calcium supplementation: balancing the cardiovascular risks. <i>Maturitas</i> , 2011 , 69, 289-95	5	25
212	Authors' response to editorial. <i>BMJ, The</i> , 2011 , 342, d3520	5.9	5
211	Decreased bone density in men on methadone maintenance therapy. <i>Addiction</i> , 2011 , 106, 349-54	4.6	41
210	Cardiovascular effects of calcium supplementation. <i>Osteoporosis International</i> , 2011 , 22, 1649-58	5.3	74
209	Re: The calcium scare: what would Austin Bradford Hill have thought?. <i>Osteoporosis International</i> , 2011 , 22, 3079-80; author reply 3081-3	5.3	7
208	Bisphosphonates in the treatment of osteoporosis: a review of their contribution and controversies. <i>Skeletal Radiology</i> , 2011 , 40, 1191-6	2.7	26
207	Odanacatib in the treatment of postmenopausal women with low bone mineral density: three-year continued therapy and resolution of effect. <i>Journal of Bone and Mineral Research</i> , 2011 , 26, 242-51	6.3	196
206	Evaluation of the FRAX and Garvan fracture risk calculators in older women. <i>Journal of Bone and Mineral Research</i> , 2011 , 26, 420-7	6.3	124
205	Effects of denosumab on bone turnover markers in postmenopausal osteoporosis. <i>Journal of Bone and Mineral Research</i> , 2011 , 26, 530-7	6.3	155
204	Once-yearly zoledronic acid and days of disability, bed rest, and back pain: randomized, controlled HORIZON Pivotal Fracture Trial. <i>Journal of Bone and Mineral Research</i> , 2011 , 26, 984-92	6.3	20

203	Evidence-based policy on dietary calcium and vitamin D. <i>Journal of Bone and Mineral Research</i> , 2011 , 26, 452-4	6.3	18
202	Calcium supplements and cardiovascular risk. <i>Journal of Bone and Mineral Research</i> , 2011 , 26, 899; author reply 900-1	6.3	4
201	Skeletal phenotype of the leptin receptor-deficient db/db mouse. <i>Journal of Bone and Mineral Research</i> , 2011 , 26, 1698-709	6.3	86
200	A single infusion of zoledronic acid produces sustained remissions in Paget disease: data to 6.5 years. <i>Journal of Bone and Mineral Research</i> , 2011 , 26, 2261-70	6.3	91
199	Calcium and vitamin D supplements and health outcomes: a reanalysis of the Women's Health Initiative (WHI) limited-access data set. <i>American Journal of Clinical Nutrition</i> , 2011 , 94, 1144-9	7	210
198	Calcium supplements with or without vitamin D and risk of cardiovascular events: reanalysis of the Women's Health Initiative limited access dataset and meta-analysis. <i>BMJ, The</i> , 2011 , 342, d2040	5.9	560
197	Stable bone density in HAART-treated individuals with HIV: a meta-analysis. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2011 , 96, 2721-31	5.6	65
196	Validation of BioDent TDI as a New Clinical Diagnostic Method. <i>Advanced Materials Research</i> , 2011 , 275, 151-154	0.5	1
195	Ghrelin is an Osteoblast Mitogen and Increases Osteoclastic Bone Resorption In Vitro. <i>International Journal of Peptides</i> , 2011 , 2011, 605193		23
194	Bisphosphonate therapy for secondary osteoporosis: adult perspective. <i>Hormone Research in Paediatrics</i> , 2011 , 76 Suppl 1, 28-32	3.3	4
193	Zoledronic acid does not reduce MRI erosive progression in PsA but may suppress bone oedema: the Zoledronic Acid in Psoriatic Arthritis (ZAPA) Study. <i>Annals of the Rheumatic Diseases</i> , 2011 , 70, 1091-4	4.4	29
192	Genome-wide association study using extreme truncate selection identifies novel genes affecting bone mineral density and fracture risk. <i>PLoS Genetics</i> , 2011 , 7, e1001372	6	199
191	Investigating harms in clinical trials - no easy task. <i>International Journal of Clinical Practice</i> , 2010 , 64, 1719-32		32
190	Does calcium supplementation increase cardiovascular risk?. <i>Clinical Endocrinology</i> , 2010 , 73, 689-95	3.4	61
189	Morbidity and mortality in mild primary hyperparathyroidism. <i>Clinical Endocrinology</i> , 2010 , 73, 688; author reply 688	3.4	1
188	Vitamin D ¶et's get back to the evidence base. <i>IBMS BoneKEy</i> , 2010 , 7, 249-253		3
187	Evidence from randomized controlled trials, meta-analyses, and subgroup analyses. <i>JAMA - Journal of the American Medical Association</i> , 2010 , 303, 1254; author reply 1254-5	27.4	3
186	Skeletal effects of interventions in mild primary hyperparathyroidism: a meta-analysis. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2010 , 95, 1653-62	5.6	72

185	Effects of calcium supplementation on lipids, blood pressure, and body composition in healthy older men: a randomized controlled trial. <i>American Journal of Clinical Nutrition</i> , 2010 , 91, 131-9	7	73
184	Characterization of and risk factors for the acute-phase response after zoledronic acid. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2010 , 95, 4380-7	5.6	172
183	Acute effect of milk on serum urate concentrations: a randomised controlled crossover trial. <i>Annals of the Rheumatic Diseases</i> , 2010 , 69, 1677-82	2.4	65
182	Vitamin D insufficiency and health outcomes over 5 y in older women. <i>American Journal of Clinical Nutrition</i> , 2010 , 91, 82-9	7	102
181	Effect of osteoporosis treatment on mortality: a meta-analysis. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2010 , 95, 1174-81	5.6	230
180	Effect of calcium supplements on risk of myocardial infarction and cardiovascular events: meta-analysis. <i>BMJ, The</i> , 2010 , 341, c3691	5.9	723
179	Fat and bone. <i>Archives of Biochemistry and Biophysics</i> , 2010 , 503, 20-7	4.1	255
178	Abdominal aortic calcification on vertebral morphometry images predicts incident myocardial infarction. <i>Journal of Bone and Mineral Research</i> , 2010 , 25, 505-12	6.3	59
177	Effects of 25-hydroxyvitamin D level and its change on parathyroid hormone in premenopausal Chinese women. <i>Osteoporosis International</i> , 2010 , 21, 1935-41	5.3	16
176	Response to publication of PRISM trial. <i>Journal of Bone and Mineral Research</i> , 2010 , 25, 1463-4; author reply 1465-6	6.3	9
175	Prolonged antiresorptive activity of zoledronate: a randomized, controlled trial. <i>Journal of Bone and Mineral Research</i> , 2010 , 25, 2251-5	6.3	49
174	Effects of denosumab on bone histomorphometry: the FREEDOM and STAND studies. <i>Journal of Bone and Mineral Research</i> , 2010 , 25, 2256-65	6.3	173
173	Relationships between vascular calcification, calcium metabolism, bone density, and fractures. <i>Journal of Bone and Mineral Research</i> , 2010 , 25, 2777-85	6.3	68
172	"Cherry picking" did not occur in studied example. <i>BMJ, The</i> , 2010 , 341, c5009	5.9	3
171	Clinical Aspects of the Use of Vitamin D and Its Metabolites in Osteoporosis 2010 , 319-331		
170	Vitamin D Deficiency and Its Health Consequences in New Zealand 2010 , 589-601		
169	Calcium and bone health: position statement for the Australian and New Zealand Bone and Mineral Society, Osteoporosis Australia and the Endocrine Society of Australia. <i>Medical Journal of Australia</i> , 2009 , 190, 316-20	4	39
168	Absence of somatic SQSTM1 mutations in Paget's disease of bone. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2009 , 94, 691-4	5.6	28

167	In vitro and in vivo effects of adiponectin on bone. <i>Endocrinology</i> , 2009 , 150, 3603-10	4.8	172
166	The antiresorptive effects of a single dose of zoledronate persist for two years: a randomized, placebo-controlled trial in osteopenic postmenopausal women. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2009 , 94, 538-44	5.6	89
165	Actions of fibroblast growth factor-8 in bone cells in vitro. <i>American Journal of Physiology - Endocrinology and Metabolism</i> , 2009 , 297, E142-50	6	18
164	Adipose Tissue and Bone. <i>Clinical Reviews in Bone and Mineral Metabolism</i> , 2009 , 7, 207-209	2.5	2
163	Adipokine Effects on Bone. <i>Clinical Reviews in Bone and Mineral Metabolism</i> , 2009 , 7, 240-248	2.5	7
162	Randomized, active-controlled study of once-weekly alendronate 280 mg high dose oral buffered solution for treatment of Paget's disease. <i>Osteoporosis International</i> , 2009 , 20, 141-50	5.3	7
161	Effect of calcium supplementation on hip fractures: reply to correspondence. <i>Osteoporosis International</i> , 2009 , 20, 835-836	5.3	4
160	High-dose oral vitamin D3 supplementation in the elderly. <i>Osteoporosis International</i> , 2009 , 20, 1407-15	5.3	120
159	Calcium supplementation for older men and women?. <i>Osteoporosis International</i> , 2009 , 20, 2147-8; author reply 2151-3	5.3	1
158	Osteonecrosis of the jaw. <i>Skeletal Radiology</i> , 2009 , 38, 5-9	2.7	29
157	Is calcium supplementation a risk factor for cardiovascular diseases in older women?. <i>Nutrition Reviews</i> , 2009 , 67, 424; author reply 425	6.4	2
156	Osteonecrosis of the jaw: who gets it, and why?. <i>Bone</i> , 2009 , 44, 4-10	4.7	205
155	Denosumab for prevention of fractures in postmenopausal women with osteoporosis. <i>New England Journal of Medicine</i> , 2009 , 361, 756-65	59.2	2189
154	Denosumab for Prevention of Fractures in Postmenopausal Women With Osteoporosis. <i>Obstetrical and Gynecological Survey</i> , 2009 , 64, 805-807	2.4	6
153	The effect of calcium supplementation on serum urate: analysis of a randomized controlled trial. <i>Rheumatology</i> , 2009 , 48, 195-7	3.9	22
152	Vitamin D and falls. Time for a moratorium on vitamin D meta-analyses?. <i>BMJ, The</i> , 2009 , 339, b4394	5.9	12
151	Vitamin D and its Metabolites and Analogs in the Management of Osteoporosis 2008 , 1659-1685		
150	Anti-resorptive therapies for osteoporosis. <i>Seminars in Cell and Developmental Biology</i> , 2008 , 19, 473-8	7.5	62

149	Pathogenesis and management of Paget's disease of bone. <i>Lancet, The</i> , 2008 , 372, 155-163	40	186
148	Calcium supplementation and vascular disease. <i>Climacteric</i> , 2008 , 11, 280-6	3.1	16
147	Vascular events in healthy older women receiving calcium supplementation: randomised controlled trial. <i>BMJ, The</i> , 2008 , 336, 262-6	5.9	455
146	Incidence of osteonecrosis of the jaw in women with postmenopausal osteoporosis in the health outcomes and reduced incidence with zoledronic acid once yearly pivotal fracture trial. <i>Journal of the American Dental Association</i> , 2008 , 139, 32-40	1.9	97
145	Randomized controlled trial of calcium supplementation in healthy, nonosteoporotic, older men. <i>Archives of Internal Medicine</i> , 2008 , 168, 2276-82		101
144	Once-yearly zoledronate-an effective preventative therapy for new fractures after hip fracture?. <i>Nature Clinical Practice Endocrinology and Metabolism</i> , 2008 , 4, 308-9		
143	Modulation of osteoclastogenesis by fatty acids. <i>Endocrinology</i> , 2008 , 149, 5688-95	4.8	107
142	Failure to detect measles virus ribonucleic acid in bone cells from patients with Paget's disease. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2008 , 93, 1398-401	5.6	51
141	Calcium supplementation and cancer incidence. <i>American Journal of Clinical Nutrition</i> , 2008 , 87, 792-3; author reply 793-4	7	10
140	Does degree of baldness influence vitamin D status?. <i>Medical Journal of Australia</i> , 2008 , 189, 674-5	4	15
139	Calcium supplementation and cancer incidence. <i>American Journal of Clinical Nutrition</i> , 2008 , 87, 792-793	7	10
138	Amylin and Calcitonin Gene-Related Peptide 2008 , 837-853		
137	Effects of intravenous zoledronic acid once yearly on bone remodeling and bone structure. <i>Journal of Bone and Mineral Research</i> , 2008 , 23, 6-16	6.3	160
136	Relationships between fat and bone. <i>Osteoporosis International</i> , 2008 , 19, 595-606	5.3	351
135	Effect of calcium supplementation on hip fractures. <i>Osteoporosis International</i> , 2008 , 19, 1119-23	5.3	94
134	Enhanced osteoclastogenesis in patients with tophaceous gout: urate crystals promote osteoclast development through interactions with stromal cells. <i>Arthritis and Rheumatism</i> , 2008 , 58, 1854-65		109
133	Effects of intravenous zoledronate on bone turnover and BMD persist for at least 24 months. <i>Journal of Bone and Mineral Research</i> , 2008 , 23, 1304-8	6.3	37
132	Pathogenesis of osteonecrosis of the jaw. <i>IBMS BoneKEy</i> , 2008 , 5, 69-77		1

131	Effects of beta-blockers on fracture risk. <i>Journal of Musculoskeletal Neuronal Interactions</i> , 2008 , 8, 105-110.	0.3	20
130	The effects of seasonal variation of 25-hydroxyvitamin D on diagnosis of vitamin D insufficiency. <i>New Zealand Medical Journal</i> , 2008 , 121, 63-74	0.8	42
129	Age-, gender-, and weight-related effects on levels of 25-hydroxyvitamin D are not mediated by vitamin D binding protein. <i>Clinical Endocrinology</i> , 2007 , 67, 259-64	3.4	68
128	Bone mineral density remains stable in HAART-treated HIV-infected men over 2 years. <i>Clinical Endocrinology</i> , 2007 , 67, 270-5	3.4	45
127	Maintaining the trust of physicians and the public in the medical literature: report of a task force on scientific publishing of clinical trials. <i>Journal of Bone and Mineral Research</i> , 2007 , 22, 1661-7	6.3	1
126	Once-yearly zoledronic acid for treatment of postmenopausal osteoporosis. <i>New England Journal of Medicine</i> , 2007 , 356, 1809-22	59.2	2094
125	Bisphosphonates. <i>Skeletal Radiology</i> , 2007 , 36, 711-4	2.7	15
124	The effect of treatment with a thiazide diuretic for 4 years on bone density in normal postmenopausal women. <i>Osteoporosis International</i> , 2007 , 18, 479-86	5.3	90
123	Vitamin D sufficiency: reply to letter by Heaney. <i>Osteoporosis International</i> , 2007 , 18, 835-836	5.3	1
122	Preptin, another peptide product of the pancreatic beta-cell, is osteogenic in vitro and in vivo. <i>American Journal of Physiology - Endocrinology and Metabolism</i> , 2007 , 292, E117-22	6	60
121	CLINICAL Review # : low body weight mediates the relationship between HIV infection and low bone mineral density: a meta-analysis. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2007 , 92, 4522-8	5.6	108
120	The peroxisome proliferator-activated receptor-gamma agonist rosiglitazone decreases bone formation and bone mineral density in healthy postmenopausal women: a randomized, controlled trial. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2007 , 92, 1305-10	5.6	358
119	Annual zoledronate increases bone density in highly active antiretroviral therapy-treated human immunodeficiency virus-infected men: a randomized controlled trial. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2007 , 92, 1283-8	5.6	111
118	Addition of monofluorophosphate to estrogen therapy in postmenopausal osteoporosis: a randomized controlled trial. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2007 , 92, 2446-52	5.6	18
117	Activation of peroxisome proliferator-activated receptor gamma (PPARgamma) by rosiglitazone suppresses components of the insulin-like growth factor regulatory system in vitro and in vivo. <i>Endocrinology</i> , 2007 , 148, 903-11	4.8	114
116	The effects of seasonal variation of 25-hydroxyvitamin D and fat mass on a diagnosis of vitamin D sufficiency. <i>American Journal of Clinical Nutrition</i> , 2007 , 86, 959-64	7	150
115	Effects of calcium supplementation on bone and other end-points in normal older women The Auckland Calcium Study. <i>International Congress Series</i> , 2007 , 1297, 82-88		
114	Alteration of bone cell function by RANKL and OPG in different in vitro models. <i>European Journal of Clinical Investigation</i> , 2007 , 37, 407-15	4.6	22

113	Long-term control of bone turnover in Paget's disease with zoledronic acid and risedronate. <i>Journal of Bone and Mineral Research</i> , 2007 , 22, 142-8	6.3	109
112	Differential gene expression in cultured osteoblasts and bone marrow stromal cells from patients with Paget's disease of bone. <i>Journal of Bone and Mineral Research</i> , 2007 , 22, 298-309	6.3	68
111	Imatinib mesylate, increased bone formation, and secondary hyperparathyroidism. <i>New England Journal of Medicine</i> , 2006 , 355, 2494-5	59.2	55
110	Emerging issues with bisphosphonates. <i>Rheumatic Disease Clinics of North America</i> , 2006 , 32, 691-702, vi	2.4	1
109	Obesity and osteoporosis. <i>Annales D'Endocrinologie</i> , 2006 , 67, 125-9	1.7	16
108	Zoledronate: efficacy and safety. <i>Journal of Bone and Mineral Research</i> , 2006 , 21 Suppl 2, P83-7	6.3	6
107	Randomized controlled trial of calcium in healthy older women. <i>American Journal of Medicine</i> , 2006 , 119, 777-85	2.4	209
106	Fat mass is an important predictor of parathyroid hormone levels in postmenopausal women. <i>Bone</i> , 2006 , 38, 317-21	4.7	111
105	Bone mineral density is not reduced in HIV-infected Caucasian men treated with highly active antiretroviral therapy. <i>Clinical Endocrinology</i> , 2006 , 65, 191-7	3.4	44
104	Bisphosphonates in pregnancy and lactation-associated osteoporosis. <i>Osteoporosis International</i> , 2006 , 17, 1008-12	5.3	120
103	Determinants of vitamin D status in older men living in a subtropical climate. <i>Osteoporosis International</i> , 2006 , 17, 1742-8	5.3	68
102	Nutrition-related peptides and bone homeostasis. <i>Journal of Bone and Mineral Research</i> , 2006 , 21, 495-500	6.3	59
101	Differences between the bisphosphonates for the prevention and treatment of osteoporosis. <i>Therapeutics and Clinical Risk Management</i> , 2006 , 2, 77-86	2.9	18
100	Steroid-Induced Osteoporosis 2006 , 689-699		
99	Comparison of the effects of pravastatin and atorvastatin on fracture incidence in the PROVE IT-TIMI 22 trial—secondary analysis of a randomized controlled trial. <i>Bone</i> , 2005 , 37, 190-1	4.7	16
98	Comparison of a single infusion of zoledronic acid with risedronate for Paget's disease. <i>New England Journal of Medicine</i> , 2005 , 353, 898-908	59.2	315
97	beta-Blocker use, BMD, and fractures in the study of osteoporotic fractures. <i>Journal of Bone and Mineral Research</i> , 2005 , 20, 613-8	6.3	121
96	Determinants of vitamin D status in older women living in a subtropical climate. <i>Osteoporosis International</i> , 2005 , 16, 1641-8	5.3	101

95	Association between primary hyperparathyroidism and increased body weight: a meta-analysis. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2005 , 90, 1525-30	5.6	154
94	Effects of calcium supplementation on body weight and blood pressure in normal older women: a randomized controlled trial. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2005 , 90, 3824-9	5.6	87
93	Effects of a beta-blocker on bone turnover in normal postmenopausal women: a randomized controlled trial. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2005 , 90, 5212-6	5.6	89
92	A comparison of the effects of raloxifene and conjugated equine estrogen on bone and lipids in healthy postmenopausal women. <i>Archives of Internal Medicine</i> , 2004 , 164, 871-9		59
91	Direct actions of leptin on bone remodeling. <i>Calcified Tissue International</i> , 2004 , 74, 313-6	3.9	19
90	Effects of calcium supplementation on circulating lipids: potential pharmacoeconomic implications. <i>Drugs and Aging</i> , 2004 , 21, 7-17	4.7	65
89	Comparative responses of bone turnover markers to bisphosphonate therapy in Paget's disease of bone. <i>Bone</i> , 2004 , 35, 224-30	4.7	84
88	Shared pathways of osteoblast mitogenesis induced by amylin, adrenomedullin, and IGF-1. <i>Biochemical and Biophysical Research Communications</i> , 2004 , 318, 240-6	3.4	44
87	Bisphosphonates: new indications and methods of administration. <i>Current Opinion in Rheumatology</i> , 2003 , 15, 458-63	5.3	39
86	Effects of vitamin D supplementation on strength, physical performance, and falls in older persons: a systematic review. <i>Journal of the American Geriatrics Society</i> , 2003 , 51, 1219-26	5.6	146
85	Efficacy of an oral, 10-day course of high-dose calciferol in correcting vitamin D deficiency. <i>New Zealand Medical Journal</i> , 2003 , 116, U536	0.8	19
84	Prospective 10-year study of the determinants of bone density and bone loss in normal postmenopausal women, including the effect of hormone replacement therapy. <i>Clinical Endocrinology</i> , 2002 , 56, 703-11	3.4	64
83	Leptin directly regulates bone cell function in vitro and reduces bone fragility in vivo. <i>Journal of Endocrinology</i> , 2002 , 175, 405-15	4.7	359
82	Effects of calcium supplementation on serum lipid concentrations in normal older women: a randomized controlled trial. <i>American Journal of Medicine</i> , 2002 , 112, 343-7	2.4	173
81	Intravenous zoledronic acid in postmenopausal women with low bone mineral density. <i>New England Journal of Medicine</i> , 2002 , 346, 653-61	59.2	714
80	Pharmacotherapy of osteoporosis in postmenopausal women: focus on safety. <i>Expert Opinion on Drug Safety</i> , 2002 , 1, 93-107	4.1	26
79	Osteoporosis: non-HRT treatments. <i>Reviews in Gynaecological Practice</i> , 2002 , 2, 48-53		2
78	Relationships among body mass, its components, and bone. <i>Bone</i> , 2002 , 31, 547-55	4.7	503

77	A new receptor to turn on bone growth. <i>New Zealand Medical Journal</i> , 2002 , 115, 169-70	0.8	
76	Determinants of sex hormone-binding globulin in normal postmenopausal women. <i>Clinical Endocrinology</i> , 2001 , 54, 81-7	3.4	30
75	Lysophosphatidic acid is an osteoblast mitogen whose proliferative actions involve G(i) proteins and protein kinase C, but not P42/44 mitogen-activated protein kinases. <i>Endocrinology</i> , 2001 , 142, 1098-106	4.8	51
74	Effects of calcitonin, amylin, and calcitonin gene-related peptide on osteoclast development. <i>Bone</i> , 2001 , 29, 162-8	4.7	133
73	Effect of pravastatin on frequency of fracture in the LIPID study: secondary analysis of a randomised controlled trial. Long-term Intervention with Pravastatin in Ischaemic Disease. <i>Lancet, The</i> , 2001 , 357, 509-12	4.0	204
72	Effects of hormone replacement therapy on bone mineral density in postmenopausal women with primary hyperparathyroidism: four-year follow-up and comparison with healthy postmenopausal women. <i>Archives of Internal Medicine</i> , 2000 , 160, 2161-6		52
71	Preventing glucocorticoid-induced osteoporosis. <i>Zeitschrift Fur Rheumatologie</i> , 2000 , 59 Suppl 2, II/97-102	0.9	5
70	Calcium supplements and nail quality. <i>New England Journal of Medicine</i> , 2000 , 343, 1817	59.2	6
69	Hydrochlorothiazide reduces loss of cortical bone in normal postmenopausal women: a randomized controlled trial. <i>American Journal of Medicine</i> , 2000 , 109, 362-70	2.4	144
68	Hormone replacement therapy causes a respiratory alkalosis in normal postmenopausal women. <i>Journal of Clinical Endocrinology and Metabolism</i> , 1999 , 84, 1997-2001	5.6	17
67	Stimulation of osteoblast proliferation by C-terminal fragments of parathyroid hormone-related protein. <i>Journal of Bone and Mineral Research</i> , 1999 , 14, 915-22	6.3	66
66	Pharmacological management of osteoporosis in postmenopausal women: a comparative review. <i>Drugs and Aging</i> , 1999 , 15, 349-63	4.7	12
65	The effect of past use of the injectable contraceptive depot medroxyprogesterone acetate on bone mineral density in normal post-menopausal women. <i>Clinical Endocrinology</i> , 1998 , 49, 615-8	3.4	80
64	Systemic administration of amylin increases bone mass, linear growth, and adiposity in adult male mice. <i>American Journal of Physiology - Endocrinology and Metabolism</i> , 1998 , 275, E694-9	6	46
63	Parathyroid hormone-related protein-(107-139) inhibits bone resorption in vivo. <i>Endocrinology</i> , 1997 , 138, 1299-304	4.8	94
62	Premature hair graying and bone mineral density. <i>Journal of Clinical Endocrinology and Metabolism</i> , 1997 , 82, 3580-3	5.6	25
61	Glucocorticoid osteoporosis--mechanisms and management. <i>European Journal of Endocrinology</i> , 1997 , 137, 209-17	6.5	195
60	Osteoporosis--emerging consensus. <i>Australian and New Zealand Journal of Medicine</i> , 1997 , 27, 643-7		5

59	Steroid-induced osteoporosis. <i>Osteoporosis International</i> , 1997 , 7 Suppl 3, S213-6	5.3	19
58	Effects of prolonged bisphosphonate therapy and its discontinuation on bone mineral density in post-menopausal osteoporosis. <i>Clinical Endocrinology</i> , 1997 , 46, 87-92	3.4	22
57	Establishing healthy bones in the young. <i>Australian Family Physician</i> , 1997 , 26, 132-4		
56	Testosterone Therapy in Glucocorticoid-Treated Men. <i>Archives of Internal Medicine</i> , 1996 , 156, 1173		217
55	Biochemical and radiologic improvement in Paget's disease of bone treated with alendronate: a randomized, placebo-controlled trial. <i>American Journal of Medicine</i> , 1996 , 101, 341-8	2.4	145
54	Insulin increases histomorphometric indices of bone formation In vivo. <i>Calcified Tissue International</i> , 1996 , 59, 492-5	3.9	121
53	Effect of hormone replacement therapy on bone mineral density in postmenopausal women with mild primary hyperparathyroidism. A randomized, controlled trial. <i>Annals of Internal Medicine</i> , 1996 , 125, 360-8	8	120
52	Medroxyprogesterone acetate enhances the spinal bone mineral density response to oestrogen in late post-menopausal women. <i>Clinical Endocrinology</i> , 1996 , 44, 293-6	3.4	38
51	Accelerated bone loss in post-menopausal women with mild primary hyperparathyroidism. <i>Clinical Endocrinology</i> , 1996 , 44, 697-702	3.4	35
50	Insulin Increases Histomorphometric Indices of Bone Formation In Vivo. <i>Calcified Tissue International</i> , 1996 , 59, 492-495	3.9	27
49	Testosterone therapy in glucocorticoid-treated men. <i>Archives of Internal Medicine</i> , 1996 , 156, 1173-7		41
48	Longer femoral necks in the young: a predictor of further increases in hip fracture incidence?. <i>New Zealand Medical Journal</i> , 1996 , 109, 234-5	0.8	3
47	Ototoxicity associated with intravenous bisphosphonate administration. <i>Calcified Tissue International</i> , 1995 , 56, 584-5	3.9	25
46	Regular exercise dissociates fat mass and bone density in premenopausal women. <i>Journal of Clinical Endocrinology and Metabolism</i> , 1995 , 80, 1764-8	5.6	69
45	Amylin stimulates osteoblast proliferation and increases mineralized bone volume in adult mice. <i>Biochemical and Biophysical Research Communications</i> , 1995 , 207, 133-9	3.4	109
44	The effect of the antiestrogen tamoxifen on bone mineral density in normal late postmenopausal women. <i>American Journal of Medicine</i> , 1995 , 99, 636-41	2.4	134
43	Long-term effects of calcium supplementation on bone loss and fractures in postmenopausal women: a randomized controlled trial. <i>American Journal of Medicine</i> , 1995 , 98, 331-5	2.4	354
42	Osteoporosis research in Auckland. <i>Clinical Science</i> , 1995 , 88, 12-4	6.5	

41	Pamidronate treatment of the neurologic sequelae of pagetic spinal stenosis. <i>Archives of Internal Medicine</i> , 1995 , 155, 1813-5		8
40	Regular exercise dissociates fat mass and bone density in premenopausal women. <i>Journal of Clinical Endocrinology and Metabolism</i> , 1995 , 80, 1764-1768	5.6	56
39	Body weight and bone mineral density in postmenopausal women with primary hyperparathyroidism. <i>Annals of Internal Medicine</i> , 1994 , 121, 745-9	8	75
38	Determinants of the rate of bone loss in normal postmenopausal women. <i>Journal of Clinical Endocrinology and Metabolism</i> , 1994 , 79, 950-4	5.6	109
37	Continuous therapy with pamidronate, a potent bisphosphonate, in postmenopausal osteoporosis. <i>Journal of Clinical Endocrinology and Metabolism</i> , 1994 , 79, 1595-9	5.6	105
36	Glucocorticoid osteoporosis. <i>Journal of Asthma</i> , 1994 , 31, 7-18	1.9	47
35	Volumetric bone density of the lumbar spine is related to fat mass but not lean mass in normal postmenopausal women. <i>Osteoporosis International</i> , 1994 , 4, 362-7	5.3	93
34	The investigation of hypercalcaemia. <i>Clinical Endocrinology</i> , 1994 , 41, 405-6	3.4	2
33	Continuous combined oestrogen/progestin therapy is well tolerated and increases bone density at the hip and spine in post-menopausal osteoporosis. <i>Clinical Endocrinology</i> , 1994 , 40, 671-7	3.4	74
32	Relation between increase in length of hip axis in older women between 1950s and 1990s and increase in age specific rates of hip fracture. <i>BMJ: British Medical Journal</i> , 1994 , 309, 508-9		64
31	Determinants of the rate of bone loss in normal postmenopausal women. <i>Journal of Clinical Endocrinology and Metabolism</i> , 1994 , 79, 950-954	5.6	97
30	Effect of calcium supplementation on bone loss in postmenopausal women. <i>New England Journal of Medicine</i> , 1993 , 328, 460-4	59.2	437
29	Circulating insulin levels are related to bone density in normal postmenopausal women. <i>American Journal of Physiology - Endocrinology and Metabolism</i> , 1993 , 265, E655-9	6	67
28	Steroid osteoporosis. <i>Osteoporosis International</i> , 1993 , 3 Suppl 1, 144-6	5.3	5
27	Lateral spine densitometry is a more sensitive indicator of glucocorticoid-induced bone loss. <i>Journal of Bone and Mineral Research</i> , 1992 , 7, 1221-5	6.3	81
26	Fat mass is an important determinant of whole body bone density in premenopausal women but not in men. <i>Journal of Clinical Endocrinology and Metabolism</i> , 1992 , 75, 779-82	5.6	275
25	Determinants of total body and regional bone mineral density in normal postmenopausal women--a key role for fat mass. <i>Journal of Clinical Endocrinology and Metabolism</i> , 1992 , 75, 45-51	5.6	353
24	Relationships between upper-arm anthropometry and soft-tissue composition in postmenopausal women. <i>American Journal of Clinical Nutrition</i> , 1992 , 56, 463-6	7	22

23	Bone mineral density of the proximal femur and lumbar spine in glucocorticoid-treated asthmatic patients. <i>Osteoporosis International</i> , 1992 , 2, 103-5	5.3	80
22	Normal bone mineral density following cure of Cushing's syndrome. <i>Clinical Endocrinology</i> , 1992 , 36, 229-34	3.4	113
21	Post-pregnancy osteoporosis associated with hypercalcaemia. <i>Clinical Endocrinology</i> , 1992 , 37, 298-303	3.4	67
20	Determinants of total body and regional bone mineral density in normal postmenopausal women--a key role for fat mass. <i>Journal of Clinical Endocrinology and Metabolism</i> , 1992 , 75, 45-51	5.6	312
19	Fat mass is an important determinant of whole body bone density in premenopausal women but not in men. <i>Journal of Clinical Endocrinology and Metabolism</i> , 1992 , 75, 779-782	5.6	261
18	Bone density in women receiving depot medroxyprogesterone acetate for contraception. <i>BMJ: British Medical Journal</i> , 1991 , 303, 13-6		190
17	The influence of osteophytes and aortic calcification on spinal mineral density in postmenopausal women. <i>Journal of Clinical Endocrinology and Metabolism</i> , 1991 , 72, 1372-4	5.6	189
16	Prevention of glucocorticoid-induced osteoporosis. <i>Journal of Bone and Mineral Research</i> , 1990 , 5, 619-23	3.3	46
15	Adenylate cyclase blockers dissociate PTH-stimulated bone resorption from cAMP production. <i>American Journal of Physiology - Endocrinology and Metabolism</i> , 1990 , 258, E708-14	6	7
14	Calcitropic hormone levels in polynesians: evidence against their role in interracial differences in bone mass. <i>Journal of Clinical Endocrinology and Metabolism</i> , 1990 , 70, 1452-6	5.6	26
13	Determinants of vertebral mineral density in patients receiving long-term glucocorticoid therapy. <i>Archives of Internal Medicine</i> , 1990 , 150, 2545-8		28
12	Steroid osteoporosis. <i>Calcified Tissue International</i> , 1989 , 45, 63-7	3.9	44
11	Insulin-like growth factor 1 and bone turnover in glucocorticoid-treated and control subjects. <i>Clinical Endocrinology</i> , 1989 , 30, 347-53	3.4	17
10	Pathogenesis and treatment of steroid osteoporosis. <i>Clinical Endocrinology</i> , 1989 , 30, 83-103	3.4	157
9	The role of dietary calcium in the pathogenesis and treatment of osteoporosis. <i>New Zealand Medical Journal</i> , 1989 , 102, 532-3	0.8	1
8	Prevention of steroid-induced osteoporosis with (3-amino-1-hydroxypropylidene)-1,1-bisphosphonate (APD). <i>Lancet, The</i> , 1988 , 1, 143-6	40	268
7	Two-year follow-up of biphosphonate (APD) treatment in steroid osteoporosis. <i>Lancet, The</i> , 1988 , 2, 1144	40	49
6	Evidence for decreased tubular reabsorption of calcium in glucocorticoid-treated asthmatics. <i>Hormone Research</i> , 1987 , 27, 200-4		83

5	The acute biochemical effects of four proprietary calcium preparations. <i>Australian and New Zealand Journal of Medicine</i> , 1986 , 16, 193-7	88
4	Parathyroid Hormone-Related Protein-(107-139) Inhibits Bone Resorption in Vivo	27
3	Lysophosphatidic Acid Is an Osteoblast Mitogen Whose Proliferative Actions Involve Gi Proteins and Protein Kinase C, But Not P42/44 Mitogen-Activated Protein Kinases	18
2	A Potential Role for Adrenomedullin as a Local Regulator of Bone Growth	15
1	Chapter 19. Menopause95-97	2